QVM149
Showing 1 - 11 of 11
Asthma Trial (QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149)
Not yet recruiting
- Asthma
- QVM149
- +7 more
- (no location specified)
Mar 18, 2023
Asthma Trial in London (QVM149, High Dose Dual Therapy (ICS/LABA))
Withdrawn
- Asthma
- QVM149
- High Dose Dual Therapy (ICS/LABA)
-
London, Ontario, CanadaRobarts Research Insitute; The University of Western Ontario; Lo
Nov 29, 2021
A 24-week rPMS Study in Real-world Setting for Enerzair
Recruiting
- Asthma
- Enerzair 150/50/80 μg
- Enerzair 150/50/160 μg
-
Suncheon, Jeollanam-do, Korea, Republic ofNovartis Investigative Site
Jun 13, 2022
Asthma Trial in Germany, Netherlands, United Kingdom (Treatment A: Matching (morning dose) and QVM149 150/50/80 µg (evening
Completed
- Asthma
- Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
- +2 more
-
Berlin, Germany
- +6 more
Dec 9, 2020
Asthma Trial in Worldwide (QVM149, Salmeterol/fluticasone plus tiotropium)
Completed
- Asthma
- QVM149
- Salmeterol/fluticasone plus tiotropium
-
Berazategui, Buenos Aires, Argentina
- +162 more
Oct 7, 2021
Asthma Trial in Worldwide (QVM149 150/50/160, QVM149 150/50/80, QMF149 150/320)
Completed
- Asthma
- QVM149 150/50/160
- +4 more
-
Bahia Blanca, Buenos Aires, Argentina
- +402 more
Jul 16, 2020
Asthma Trial (Glycopyrronium bromide 25ug, Placebo, Glycopyrronium bromide 12.5ug)
Recruiting
- Asthma
- Glycopyrronium bromide 25ug
- +2 more
-
Ruse, Bulgaria
- +11 more
Jan 23, 2023